YIH
VERV

Y-Intercept (HK)’s Verve Therapeutics VERV Stock Holding History

Y-Intercept (HK)’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,736
Closed -$289K – 2081
2025
Q2 		$289K Sell
25,736
-25,705
-50% -$147K 0.01% 1370
2025
Q1 		$235K Buy
+51,441
New +$345K 0.02% 999

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Y-Intercept (HK)'s VERV Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 25,736 shares — an estimated $289K sold.

Y-Intercept (HK) first reported a position in VERV in Q1 2025 and held it in 2 quarters. The position peaked at $289K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 25,736 Verve Therapeutics shares in Q3 2025, an estimated $289K.
  • Y-Intercept (HK) first reported a position in Verve Therapeutics in Q1 2025 and held it in 2 quarters.
  • Y-Intercept (HK)'s Verve Therapeutics position peaked at $289K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.